Comparative efficacy of cemiplimab versus other systemic treatments for advanced cutaneous squamous cell carcinoma-Reference-Cited by-同舟云学术

Comparative efficacy of cemiplimab versus other systemic treatments for advanced cutaneous squamous cell carcinoma

Published:2021-02 Issue:5 Volume:17 Page:611-627
ISSN:1479-6694
Container-title:Future Oncology
language:en
Short-container-title:Future Oncology

Author:

Keeping Sam¹^ORCID,Xu Yingxin²,Chen Chieh-I²,Cope Shannon¹,Mojebi Ali¹,Kuznik Andreas²,Konidaris Gerasimos³,Ayers Dieter¹,Sasane Medha⁴,Allen Rachel³,Huynh Thi-Minh-Thao⁵,Popoff Evan¹,Freeman Morganna⁶,Andria Michael L²,Fury Matthew G²,Singh Kanwarjit⁴,Stockfleth Eggert⁷,Challapalli Amarnath⁸,Schmults Chrysalyne D⁹

Affiliation:

1. Precision HEOR, Vancouver, BC V6H 3Y4, Canada

2. Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA

3. Sanofi, Reading, RG6 1PT, UK

4. Sanofi, Bridgewater, NJ 08807, USA

5. Sanofi, Chilly-Mazarin, 91380, France

6. City of Hope, Duarte, CA 91010, USA

7. Department of Dermatology, University of Bochum, 44801 Bochum, Germany

8. Bristol Cancer Institute, University Hospitals Bristol NHS Foundation Trust, Bristol, BS2 8ED, UK

9. Brigham & Women’s/Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA

Abstract

Aim: To estimate the comparative efficacy of cemiplimab, a programmed cell death protein 1 inhibitor, versus EGFR inhibitors, pembrolizumab and platinum-based chemotherapy in terms of overall survival (OS) and progression-free survival. Patients & methods: We performed an indirect treatment comparison of cemiplimab and other available systemic therapies for patients with advanced cutaneous squamous cell carcinoma. Results: Cemiplimab was associated with benefits in OS (hazard ratios range: 0.07–0.52) and progression-free survival (hazard ratios range: 0.30–0.67) versus EGFR inhibitors and pembrolizumab (data from KEYNOTE-629). Cemiplimab was more efficacious versus platinum-based chemotherapy in terms of OS. Conclusion: Cemiplimab may offer improvements in survival for advanced cutaneous squamous cell carcinoma patients compared with existing systemic therapies.

Funder

Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme

Publisher

Future Medicine Ltd

Subject

Cancer Research,Oncology,General Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/fon-2020-0823

Reference99 articles.

1. Incidence Estimate of Nonmelanoma Skin Cancer (Keratinocyte Carcinomas) in the US Population, 2012

2. Estimating Increases in Skin Cancer Morbidity Due to Increases in Ultraviolet Radiation Exposure

3. Squamous cell carcinoma of the skin (excluding lip and oral mucosa)

4. Risk of Aggressive Skin Cancers After Kidney Retransplantation in Patients With Previous Posttransplant Cutaneous Squamous Cell Carcinomas

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Checkpoint Inhibitors in Dogs: Are We There Yet?;Cancers;2024-05-24

2. Dissection of an impact of VDR and RXRA on the genomic activity of 1,25(OH)2D3 in A431 squamous cell carcinoma;Molecular and Cellular Endocrinology;2024-03

3. Unresectable auricular squamous cell carcinoma with locoregional metastasis: use of cemiplimab in an immunosuppressed patient;Anais Brasileiros de Dermatologia;2024-01

4. Neoadjuvant Approaches to Non-Melanoma Skin Cancer;Cancers;2023-11-21

5. The Novel Checkpoint Target Lymphocyte-Activation Gene 3 Is Highly Expressed in Cutaneous Squamous Cell Carcinoma;Dermatologic Surgery;2023-11-07